Lara Sullivan, Pyxis Oncology CEO
August 15, 2022 11:15 AM EDT
R&D

Pyx­is tak­ing scalpel to pre­clin­i­cal pipeline, stops de­vel­op­ment on half — for now

Paul Schloesser

Associate Editor

A Cam­bridge, MA biotech is look­ing to push to the clin­ic, and it’s will­ing to throw oth­er can­di­dates to the way­side.

Pyx­is On­col­o­gy put out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

A service from the Financial Times